Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Potency, selectivity, and consequences of nonselectivity of PDE inhibition

Abstract

Phosphodiesterases (PDEs) play a decisive role in cyclic nucleotide-mediated intracellular signaling. As PDEs are expressed in a variety of tissues, selectivity is a prerequisite for a therapeutically applicable PDE inhibitor. Sildenafil, vardenafil, and tadalafil are selective for PDE5, with vardenafil exhibiting the highest potency and minimal inhibition of other PDEs, with the exception of PDE6. Tadalafil is extremely selective for PDE5, but also potently inhibits PDE11, an enzyme with unknown physiological function. As PDE1 is expressed in the brain, myocardium, and vascular smooth muscle cells, nonselectivity with respect to this enzyme (selectivity: tadalafil>vardenafil>sildenafil) may result in vasodilation and tachycardia. Inhibition of PDE6 (selectivity: tadalafil>vardenafilsildenafil), which is expressed only in retina and functions in visual transduction, can transiently disturb vision. PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophospate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Saenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.

    CAS  Article  Google Scholar 

  2. Porst H . IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S57–S64.

    Article  Google Scholar 

  3. Turko IV, Ballard SA, Francis SH, Corbin JD . Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124–130.

    CAS  Article  Google Scholar 

  4. Saenz de Tejada I, Frutos JA, Gaudo M, Florio V . Comparative selectivity: profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14(Suppl 4): S20–S32.

    Google Scholar 

  5. Corbin JD, Francis SH . Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 277: 47581–47587.

    Google Scholar 

  6. Gbekor E et al. Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 2002; 42(Suppl 1): 63.

    Article  Google Scholar 

  7. Kim NN et al. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel selective phosphodiesterase type 5 inhibitor. Life Sci 2001; 69: 2249–2256.

    CAS  Article  Google Scholar 

  8. Bardou M et al. Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol 2001; 38: 325–334.

    CAS  Article  Google Scholar 

  9. Stief CG . Phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drugs Today 2000; 36: 93–99.

    CAS  Article  Google Scholar 

  10. Moreland RB, Goldstein II, Kim NN, Traish A . Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor. Trends Endocrinol Metab 1999; 10: 97–104.

    CAS  Article  Google Scholar 

  11. McGrouther C et al. Biochemical in situ hybridisation (ISH) and immunohistochemical (ICH) characterisation of phosphodiesterase type 5 (PDE5) expression in human corpus cavernosum (CC) and cardiac tissue. Int J Impot Res 2000; 12(Suppl 1): S27.

    Google Scholar 

  12. Burslem M, Harrow J, Lanfear I, Phillips SC . Modulation of PDE11A activity. Patent # EP 12 11 313 A2, 2002.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E Bischoff.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16, S11–S14 (2004). https://doi.org/10.1038/sj.ijir.3901208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901208

Keywords

  • phosphodiesterase inhibitors
  • 3′,5′-cyclic-nucleotide phosphodiesterase
  • sildenafil
  • vardenafil
  • tadalafil

Further reading

Search

Quick links